Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Dermatologic 1

Conditions

Melanoma 10Lymphoma, T-Cell, Cutaneous 5Mycosis Fungoides 4Sezary Syndrome 3Uveal Melanoma 2Urinary Bladder Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma, T-Cell 2Lung Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Mesothelioma, Malignant 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Infliximab 2Fecal Microbiota Transplantation 2vedolizumab 1Prednisone 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Loperamide 1LDP-02 1Immunoglobulin G 1Disulfides 1CT-P13 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colitis × Disulfides × Dermatologic × Clear all
NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡